Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy

(2020) Jordan E Lake et al.   CLINICAL INFECTIOUS DISEASES

Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV

(2020) Pere Domingo et al.   INTERNATIONAL JOURNAL OF OBESITY

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

(2020) Carrie McMahon et al.   PLoS One

The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes

(2020) Jennifer Gorwood et al.   CLINICAL INFECTIOUS DISEASES

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

(2020) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study

(2020) Axel Ursenbach et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2020) Kenneth H Mayer et al.   LANCET

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz

(2020) Rulan Griesel et al.   CLINICAL INFECTIOUS DISEASES

Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens

(2020) Michael A Leonard et al.   CLINICAL INFECTIOUS DISEASES

Mitochondrial DNA haplogroups and weight gain following switch to INSTI-Based ART

(2020) Kristine M. Erlandson et al.   AIDS

Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV

(2020) Cecile D. Lahiri et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

(2019) Willem D.F. Venter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients

(2019) Chloe Orkin et al.   AIDS

Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries

(2018) Pragna Patel et al.   AIDS

Adipocytes impair efficacy of antiretroviral therapy

(2018) Jacob Couturier et al.   ANTIVIRAL RESEARCH

Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy

(2018) Vanessa El Kamari et al.   CLINICAL INFECTIOUS DISEASES

Brief Report

(2017) Jamison Norwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Neural Control of Energy Balance: Translating Circuits to Therapies

(2015) Laurent Gautron et al.   CELL

Weight Change After Antiretroviral Therapy and Mortality

(2015) B. Yuh et al.   CLINICAL INFECTIOUS DISEASES

Sexually different actions of leptin in proopiomelanocortin neurons to regulate glucose homeostasis

(2008) Haifei Shi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM